Skip to Main Content

Paper Details

Comparative effectiveness of natalizumab ocrelizumab in multiple sclerosis: a real-world propensity score-matched study.
0
2022
NfL, Ocrelizumab, Patients, RRMS, multiple sclerosis, natalizumab, neurofilament light chain, ocrelizumab, patients, relapsing-remitting multiple sclerosis, serum
Author NameAffiliation
Frauke ZippUniversity Medical Center of the Johannes Gutenberg University Mainz
  • 1 - 1

Datasets

Release 1.2